A Clinical Practice-Based Comparison of Conventional and Individualized Dosing Strategies for Therapeutic Enoxaparin.

To understand differences in anti-factor-Xa levels produced by two different dosing strategies (conventional and individualized) for therapeutic enoxaparin in a cohort of hospital inpatients. A multicenter, retrospective cohort study over a two- and a half-year period for inpatients with stable renal function and on therapeutic enoxaparin. Anti-factor-Xa levels were taken 3-5 h after enoxaparin administration and a minimum of 48 h of dosing.

Words to Avoid During Wide-awake Local Anesthesia No Tourniquet Surgery to Enhance Patient Experience.

In the evolving landscape of ambulatory surgery, wide-awake local anesthesia no tourniquet (WALANT) surgery has emerged as a preferred approach due to its efficacy, cost-effectiveness, and patient satisfaction. This paradigm shift places the patient at the center of intraoperative communication, requiring a significant change in the dialogue within the operating room (OR). Traditional conversations, which often exclude the unconscious patient, must evolve to accommodate and prioritize the psychological comfort of the conscious patient.

Understanding low-threshold mode-locking at multi-GHz repetition rate.

Continuous-wave mode-locking at multi-GHz repetition rates is achieved in an ultrashort laser cavity at critical pulse energies 100 times lower than predicted by conventional theory. The authors reveal that dynamic gain depletion and recovery between consecutive round-trips is the key factor behind a low-pulse-energy transition from Q-switched mode-locking (QSML) to continuous-wave mode-locking (CWML). As well as providing new insight into gain dynamics, the results suggest a practical route to low-threshold lasing at very high-repetition rates.

Determination of the optimal obesity-adjusted dosing weight for enoxaparin.

Aims: The ideal dosing weight metric for enoxaparin remains elusive. Dosing remains focused on actual body weight, which may inadvertently increase the risk of bleeding in those with obesity, or ideal weight, which may underdose those with obesity. Our aim was to determine the optimal obesity-adjusted enoxaparin dosing weight.